摘要
伊马替尼作为第一代酪氨酸激酶抑制剂,给Ph+慢性髓性白血病(CML)患者带来了革命性的疗效,NCCN及ELN将其推荐为CML的首选治疗。但伊马替尼存在治疗费用高且不能停药、产生耐药、更长期的疗效尚待观察等限制。依据我国的国情,中国CML实践推荐针对不同患者,给予TKI、HSCT、干扰素及细胞毒药物结合的个体化治疗。
Imatinib mesylate, as the first generation Bcr-Abl tyrosine kinase inhibitor, has brought revolutionary treatment for Philadelphia chromosome （Ph）-positive chronic myelogenous leukemia （CML） ;it has been rec- ommended as the first-line treatment for CML by NCCN Practice Guidelines in Oncology in 2008 and European LeukemiaNet（ELN） criteria. However, imatinib has three limitations ：first, it is expensive and can not be stopped if efficancy to be maintained ;Second, some 20% -30% of patients develope resistance to imatinib;and third, the CML patients can not be cured with imatinib. Taking into consideration of the situation in China, we recommend individual therapy using TKI, HSCT, interferon and cytotoxic drugs for CML patients in China.
出处
《中国实用内科杂志》
CAS
CSCD
北大核心
2010年第1期32-34,共3页
Chinese Journal of Practical Internal Medicine
基金
教育部创新团队(IRT0702)
关键词
慢性髓性白血病
造血干细胞移植
伊马替尼
chronic myelogenous leukemia
hematopoetic stem cell transplantation
imatinib
